Acute myeloid leukemia antibody flunks trials

blood cells.jpg

A Phase IIb study of the monoclonal antibody lintuzumab, also known as SGN33, failed to demonstrate an improvement in overall survival compared to current chemotherapy …

Read more about this story at CancerTreatment.net.

By Ross Bonander

LymphomaInfo Social